Overview

Effectiveness of Remedesvir in COVID-19 Patients Presenting at Mayo Hospital Lahore

Status:
Completed

Trial end date:
2020-12-30

Target enrollment:
0

Participant gender:
All

Summary

Currently, several drugs including Remdesivir, hydroxychloroquine, chloroquine, ritonavir+lopinavir, Tocilizumab, Arbidol and interferon are under randomised controlled trials (RCTs) for efficacy and/or safety evaluations in patients with COVID-19 in different countries. Remdesivir (GS-5734) is among these investigational drugs and some studies reported promising results. Remdesivir is a nucleotide analogue intravenous pro-drug developed by Gilead Sciences, an American biopharmaceutical company, for treatment of Ebola virus during the 2014 Ebola outbreak in Western Africa. Remdesivir shows broad-spectrum antiviral activity against many RNA viruses including SARS-CoV-2 through blocking RNA polymerase thereby terminating RNA transcription. Remdesivir was among the first treatments used in China as the outbreak emerges and it has been reported as potential treatment options for COVID-19 in the USA, China and Italy.

Phase:

N/A

Accepts Healthy Volunteers?

Details

Lead Sponsor:

King Edward Medical University

Treatments:

Azithromycin
Dexamethasone
Methylprednisolone Hemisuccinate
Prednisolone
Remdesivir

Criteria

Inclusion Criteria:

1. All Patients with confirmed COVID-19 of either gender and aged 12 years and above.

2. Patients having Severe COVID 19 Disease. Severe disease is defined as patients with an
oxygen saturation (SpO2) ≤94% on room air or requiring supplemental oxygen or
requiring mechanical ventilation or requiring extracorporeal membrane oxygenation
(ECMO).17

-

Exclusion Criteria:

1. Known severe allergic reaction to Remdesivir or to other antiviral drugs

2. Patients already having other treatments like tocilizumab or other antiviral drugs

3. Pregnancy or breastfeeding

4. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >5 times upper
normal limit

5. Creatinine clearance <30ml/min

6. Low platelet count <50,000/l